Results 101 to 110 of about 95,577 (390)

Physics of Protein Aggregation in Normal and Accelerated Brain Aging

BioEssays, EarlyView.
Soluble monomeric proteins precipitate via nucleation into insoluble amyloids in response to age‐related exposures (e.g., microbes, nanoparticles). Persistent soluble‐to‐insoluble phase transition depletes the functional proteins. In normal aging, replacement matches loss; in accelerated aging, it does not.
Alberto J. Espay, Andrea Sturchio, Alberto Imarisio, Emily J. Hill, Brady Williamson, Kora Montemagno, Christian Hoffmann, Hugo Le Roy, Dragomir Milovanovic, Fredric P. Manfredsson   +9 more
wiley   +1 more source

Functional correlates of optic flow motion processing in Parkinson’s disease [PDF]

, 2014
The visual input created by the relative motion between an individual and the environment, also called optic flow, influences the sense of self-motion, postural orientation, veering of gait, and visuospatial cognition.
Cronin-Golomb, Alice, Norton, Daniel J., Putcha, Deepti, Rosen, Maya L., Ross, Robert S., Somers, David C., Stern, Chantal E.   +6 more
core   +5 more sources

Manganese Neurotoxicity and Familial Disorders of Manganese Transport

Annals of the Child Neurology Society, EarlyView.
ABSTRACT Manganese is the 12th most common element in the Earth's crust and is an essential industrial component. Biologically, this metal plays an important role as a constituent of numerous enzymes. While manganese is required for normal biochemical and physiological processes, manganese excess can lead to significant toxicity, particularly to the ...
Sidney M. Gospe Jr.
wiley   +1 more source

Vascular disease and vascular risk factors in relation to motor features and cognition in early Parkinson's disease [PDF]

, 2016
Funded by Parkinson's UK National Institute for Health Research (NIHR) DeNDRoN network NIHR Newcastle Biomedical Research Unit Newcastle University NIHR funded Biomedical Research Centre in CambridgePeer reviewedPublisher ...
Bajaj, Nin, Barker, Roger A, Ben-Shlomo, Yoav, Burn, David J, Grosset, Donald G, Grosset, Katherine A, Hardy, John, Lawton, Michael A, Malek, Naveed, Marrinan, Sarah L, Morris, Huw R, PRoBaND Clinical Consortium, Swallow, Diane M A, Williams, Nigel M, Wood, Nicholas   +14 more
core   +5 more sources

Progress of non‐motor symptoms in early‐onset Parkinson's disease

Ibrain, EarlyView.
This study reviews the research progress related to non‐motor symptoms (NMS) in patients with early onset Parkinson's disease (EOPD), including neuropsychiatric symptoms, autonomic dysfunction, sleep disorders, and sensory disorders and also summarizes the characteristics of NMS in the genetic form of Parkinson's disease (PD).
Fanshi Zhang, Aidi Luo, Shusheng Liao, Mei Liu, Jun Zhang, Zucai Xu   +5 more
wiley   +1 more source

Contributions of Gut Bacteria and Diet to Drug Pharmacokinetics in the Treatment of Parkinson's Disease

Frontiers in Neurology, 2019
Parkinson's disease is the second-most common neurodegenerative disorder worldwide. Besides deciphering the mechanisms that underlie the etiology of the disease, it is important to elucidate the factors that influence the efficacy of the treatment ...
Sebastiaan P. van Kessel, Sahar El Aidy
doaj   +1 more source

Development of a controlled-release anti-parkinsonian nanodelivery system using levodopa as the active agent. [PDF]

, 2013
A new layered organic-inorganic nanocomposite material with an anti-parkinsonian active compound, L-3-(3,4-dihydroxyphenyl) alanine (levodopa), intercalated into the inorganic interlayers of a Zn/Al-layered double hydroxide (LDH) was synthesized using a ...
Arulselvan, Palanisamy, Fakurazi, Sharida, Hussein Al Ali, Samer Hasan, Hussein, Mohd. Zobir, Kura, Aminu Umar   +4 more
core   +2 more sources

Somatic cell reprogramming for Parkinson's disease treatment

Ibrain, Volume 11, Issue 1, Page 59-73, Spring 2025.
The fundamental purpose of cell reprogramming to treat Parkinson's disease is to generate dopaminergic neurons (DAN) and do transplantation. There are two ways to accomplish this. One method is to induce cells into induced DA neurons (iDAN) directly or to induce cells into induced pluripotent stem cells and ultimately into iDAN in vitro. Another option
Xiaozhuo Li, Kevin Fang, Fengping Wang
wiley   +1 more source

PET Studies of Cerebral Levodopa Metabolism: A Review of Clinical Findings and Modeling Approaches [PDF]

, 2009
[18F]Fluoro-3,4-dihydroxyphenyl-l-alanine (FDOPA) was one of the first successful tracers for molecular imaging by positron emission tomography (PET), and has proven immensely valuable for studies of Parkinson’s disease.
Cumming, Paul, Kumakura, Yoshitaka
core   +1 more source

The Gut‐Brain Axis in Parkinson disease: Emerging Concepts and Therapeutic Implications

Movement Disorders Clinical Practice, EarlyView.
Abstract Background The gut‐brain axis, i.e. the bidirectional communication system between the gut and the brain, has become of central importance in Parkinson disease (PD) research over the past 20 years. Aims We aimed to describe the milestones of the gut‐brain axis research in PD and the development of theories proposing the involvement of the ...
Elisa Menozzi, Anthony H.V. Schapira, Per Borghammer   +2 more
wiley   +1 more source